TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06109584

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of central venous catheter
Description: Central venous catheter verified by ultrasound and then verified by radiography.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of central venous catheter
Description: Central venous catheter verified by ultrasound and then verified by radiography.
Study: NCT05212077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced Care at Home (ACH)
Description: Inpatient hospitalization offered in the home setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Brick-and-Mortar Hospitalization
Description: Inpatient hospitalization offered in the hospital setting.
Study: NCT06278896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cessation of antibiotics
Description: Stop antibiotic therapy after episode of fever if afebrile for 48 hours, no clinically documented source of bacterial infection, and no hemodynamic or respiratory decompensation.
Study: NCT04599478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and Bupropion medication
Description: NB medication will be taken daily in pill form.
Study: NCT05639556

Intervention type: DIAGNOSTIC_TEST
Intervention: Hologic Dual X-Ray Absorptiometry (DXA)
Description: DXA measurements for whole body, total hip and lumbar spine will be acquired using the Hologic DXA and standard positioning as noted in the DXA Manual of Operations. DXA will be used to estimate total and regional body composition, which will include body fat and lean body mass. This will be used as the gold standard from which to validate BIA and MAMC.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hologic Dual X-Ray Absorptiometry (DXA)
Description: DXA measurements for whole body, total hip and lumbar spine will be acquired using the Hologic DXA and standard positioning as noted in the DXA Manual of Operations. DXA will be used to estimate total and regional body composition, which will include body fat and lean body mass. This will be used as the gold standard from which to validate BIA and MAMC.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Sub-study of assessment of appendage muscles using ultrasound
Description: A minimum of 50 individuals will be enrolled. At each study visit, participants will undergo ultrasound muscle measurements (cross-sectional area and muscle thickness) of the biceps and quadriceps on each (left and right) side of the body (4 total areas). These measurements will be obtained in triplicate for each patient.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Sub-study of assessment of appendage muscles using ultrasound
Description: A minimum of 50 individuals will be enrolled. At each study visit, participants will undergo ultrasound muscle measurements (cross-sectional area and muscle thickness) of the biceps and quadriceps on each (left and right) side of the body (4 total areas). These measurements will be obtained in triplicate for each patient.

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychosocial questionnaire: Hunger Vital Sign questionnaire
Description: Screening tool for identifying households at risk of food insecurity and poor health outcomes linked to food insecurity with 3-items over the last 12 months.
Study: NCT05043389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofunctional therapy program
Description: Exercise oral cavity muscle
Study: NCT04747587

Intervention type: OTHER
Intervention: Reaching Session
Description: Two x 45 minutes sessions of reaching tasks. Patients in the stroke group will perform the task with the paretic arm using a weight reduction system, allowing movement in the horizontal plane.~Subjects in the control group will perform the task with the randomly selected arm weighted at 80% of their maximum voluntary shoulder torque

Intervention type: OTHER
Intervention: Reaching Session
Description: Two x 45 minutes sessions of reaching tasks. Patients in the stroke group will perform the task with the paretic arm using a weight reduction system, allowing movement in the horizontal plane.~Subjects in the control group will perform the task with the randomly selected arm weighted at 80% of their maximum voluntary shoulder torque
Study: NCT05185050

Intervention type: DIAGNOSTIC_TEST
Intervention: physical examination and measurement of spinal alignment
Description: physical examination for scoliosis and myofascial pain syndrome, measurement of spinal coronal and sagittal alignment in X-ray, and pain intensity (with Visual analog scale) if necessary (for MPS group)

Intervention type: DIAGNOSTIC_TEST
Intervention: physical examination and measurement of spinal alignment
Description: physical examination for scoliosis and myofascial pain syndrome, measurement of spinal coronal and sagittal alignment in X-ray, and pain intensity (with Visual analog scale) if necessary (for MPS group)
Study: NCT05003596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Tablet
Description: Subjects will take a quantity 21 4mg tablets over a 6 week taper.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Mobilization Treatment
Description: standard treatment of hand injuries with focus on mobilization. No anti-inflammatory medications. Pain management via Tylenol or narcotics if deemed necessary.
Study: NCT04880369

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy isoflavones
Description: Commercially available dietary supplement (capsule) containing 60 mg isoflavones (genistein, daidzein and glycitein).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lignans
Description: Commercially available dietary supplement (capsule) containing 63 mg lignans (secoisolaricirecinol)
Study: NCT04599478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss
Description: Behavioral Weight Loss (BWL) counseling includes weekly sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss
Description: Behavioral Weight Loss (BWL) counseling includes weekly sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be inactive and taken daily in pill form.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be inactive and taken daily in pill form.
Study: NCT05639556

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychosocial questionnaire: Hunger Vital Sign questionnaire
Description: Screening tool for identifying households at risk of food insecurity and poor health outcomes linked to food insecurity with 3-items over the last 12 months.
Study: NCT05463640

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADGRE2 CAR-T
Description: ADGRE2 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
Study: NCT04880369

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules are supplied and packaged by Region Hovedstadens Apotek (Denmark) and will contain lactose monohydrate, potato starch, gelatin, magnesium stearate and talc.
Study: NCT06141265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
Study: NCT05179525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone ISM® 100 mg
Description: 100 mg of risperidone ISM® administered every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperdal 4mg Tablet
Description: 4 mg oral risperidone once daily for 7 days
Study: NCT05639556

Intervention type: OTHER
Intervention: Respiratory symptom questionnaire: CRISS
Description: Chronic Respiratory Infection Symptom Score (CRISS) is an 8-item respiratory symptom questionnaire covering the last 24-hours.

Intervention type: OTHER
Intervention: Respiratory symptom questionnaire: CRISS
Description: Chronic Respiratory Infection Symptom Score (CRISS) is an 8-item respiratory symptom questionnaire covering the last 24-hours.
Study: NCT06054139

Intervention type: OTHER
Intervention: Refeeding Syndrome
Description: Patients who developed Refeeding Syndrome despite proper nutrition while receiving treatment in the ICU
Study: NCT05494047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetravalent influenza vaccine developed by Sinovac Biotech Co.
Description: 15μg Hemagglutinin Antigen (HA) of each of the four strains

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetravalent influenza vaccine developed by Sinovac Biotech Co.
Description: 15μg Hemagglutinin Antigen (HA) of each of the four strains
Study: NCT04511858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maximum effort test on a cycloergometer
Description: 5 h test on cycloergometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maximum effort test on a treadmill
Description: 5 h test on treadmill
Study: NCT05165758

Intervention type: OTHER
Intervention: Self-assessment questionnaires
Description: Subjects will pass the SF-36 score (mental health items) and the EPICES index

Intervention type: OTHER
Intervention: Self-assessment questionnaires
Description: Subjects will pass the SF-36 score (mental health items) and the EPICES index
Study: NCT04918511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPD5
Description: OPD5 solution for i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPD5
Description: OPD5 solution for i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPD5
Description: OPD5 solution for i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPD5
Description: OPD5 solution for i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPD5
Description: OPD5 solution for i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPD5
Description: OPD5 solution for i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPD5
Description: OPD5 solution for i.v. infusion
Study: NCT05374551

Intervention type: OTHER
Group type: OTHER
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation will be used to stimulate brain activity in a brain region of experimental interest (lateral parietal cortex) and in a control brain region (vertex). All participants will experience both forms of stimulation, in separate sessions. Stimulation will be applied as a probe to understand the basic phenomenon of how brain processes support episodic memory.
Study: NCT05745519

Intervention type: OTHER
Intervention: Pittsburgh sleep quality index (PSQI)
Description: The scale is suitable for the evaluation of sleep quality in patients with sleep disorders and mental disorders, as well as for the evaluation of sleep quality in general people.

Intervention type: OTHER
Intervention: Pittsburgh sleep quality index (PSQI)
Description: The scale is suitable for the evaluation of sleep quality in patients with sleep disorders and mental disorders, as well as for the evaluation of sleep quality in general people.

Intervention type: DEVICE
Intervention: ANSWatch
Description: Measure eight physiological parameters including heartbeat, systolic blood pressure, diastolic blood pressure, heart rhythm variability HRV, low frequency component LF, high frequency component HF, LF/HF low frequency high frequency component ratio, and irregular heartbeat within five minutes
Study: NCT05639556

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: Spirometry will be performed in accordance with the current American Thoracic Society recommendations for the performance and interpretation of tests.
Study: NCT05745519

Intervention type: DEVICE
Intervention: ANSWatch
Description: Measure eight physiological parameters including heartbeat, systolic blood pressure, diastolic blood pressure, heart rhythm variability HRV, low frequency component LF, high frequency component HF, LF/HF low frequency high frequency component ratio, and irregular heartbeat within five minutes
Study: NCT05639556

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: Spirometry will be performed in accordance with the current American Thoracic Society recommendations for the performance and interpretation of tests.

Intervention type: OTHER
Intervention: Psychosocial questionnaire: Additional Health Questionnaire
Description: Single question over the last 3 months/90 days about cannabis use for GI problems and appetite. The clinical sites will not see the responses to this question. It will be completed by the participant online either during the study visit or at home.
Study: NCT05465291

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: This group will receive passive/active range of motion (ROM) exercises. ROM exercises will include major muscle groups (i.e. biceps, triceps, and lower limbs) and will be applied from second day till seventh day of admission .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Muscle Stimulation group
Description: * Patients in NEMS group will receive neuromuscular electrical stimulation from second day till seventh day of admission.~* Neuromuscular electrical stimulation will be implemented simultaneously on the rectus femoris, vastus lateralis, and vastus medialis muscles of both lower limbs, with two stimulators, in two 30-min sessions per day starting from the second day till seventh day of admission .
Study: NCT05639556

Intervention type: OTHER
Intervention: Psychosocial questionnaire: Additional Health Questionnaire
Description: Single question over the last 3 months/90 days about cannabis use for GI problems and appetite. The clinical sites will not see the responses to this question. It will be completed by the participant online either during the study visit or at home.
Study: NCT05049174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nuse-led interview and referral to municipal healthy life-centres
Description: Usual care treatment and written information to patients and general practitionnaires about smoking cessation and the municipal healthy life-centres

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nuse-led interview and referral to municipal healthy life-centres
Description: Usual care treatment and written information to patients and general practitionnaires about smoking cessation and the municipal healthy life-centres
Study: NCT05465291

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Muscle Stimulation and Exercise group
Description: Patients in this group will be subjected to Neuromuscular Electrical Muscle Stimulation and Exercise.
Study: NCT06092905

Intervention type: OTHER
Intervention: Endoscopic clearance of common bile duct stones
Description: Under general anesthesia, in left lateral decubitus, endoscopic clearance of common bile duct stones was done. Ultrasonography was used to ensure right positioning of the guide wire in the common bile duct, and ensure stone clearance.
Study: NCT04784559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin
Description: Plitidepsin 2 mg powder is provided as a sterile, preservative-free, and white to off-white lyophilised powder/cake comprising 2 mg plitidepsin and mannitol in a single-dose, 10 mL clear type 1 glass vial.~Solvent for plitidepsin is provided as a sterile, preservative-free, clear, slightly viscous aqueous liquid (4 mL) containing macrogolglycerol ricinoleate and ethanol in a single-dose type 1 clear glass ampoule.~For administration, vial contents are reconstituted by addition of 4 mL of solvent for plitidepsin to obtain a slightly yellowish solution containing 0.5 mg/mL plitidepsin with mannitol, macrogolglycerol ricinoleate and ethanol excipients. The required amount of plitidepsin reconstituted solution is added to bag containing 0.9% sodium chloride or 5% glucose for IV injection and administered as an IV infusion over 60 minutes.
Study: NCT06581302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic seizure therapy by Magnetic stimulator
Description: The seizure is induced by Magnetic stimulator of MagPro MST(XP)，MagVenture A/S, Farum, Denmark. It is administered in combinations with antipsychotic medications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc)
Description: It mainly includes second-generation antipsychotic medications, such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc, but except clozapine.
Study: NCT06582381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal set A
Description: morning meal: low carbohydrate, low protein, low fat afternoon meal: high carbohydrate, high protein, high fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal set A
Description: morning meal: low carbohydrate, low protein, low fat afternoon meal: high carbohydrate, high protein, high fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal set B
Description: morning meal: low carbohydrate, high protien, low fat meal afternoon meal: high carbohydrate, low protein, high fat meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal set B
Description: morning meal: low carbohydrate, high protien, low fat meal afternoon meal: high carbohydrate, low protein, high fat meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal set C
Description: morning meal: low carbohydrate, low protien, low fat meal afternoon meal: high carbohydrate, high protein, low fat meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal set C
Description: morning meal: low carbohydrate, low protien, low fat meal afternoon meal: high carbohydrate, high protein, low fat meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal set D
Description: morning meal: high carbohydrate, low protien, low fat meal afternoon meal: low carbohydrate, high protein, high fat meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal set D
Description: morning meal: high carbohydrate, low protien, low fat meal afternoon meal: low carbohydrate, high protein, high fat meal
Study: NCT04998656

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Werewolf FLOW 50
Description: Use of Werewolf FLOW 50 electrocautery device during surgical treatment for ACL injury. This device is often used as standard of care when our other standard of care approach (use of no electrocautery device) is not used.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Use of no electrocautery device during surgical treatment for ACL injury. This approach is often used as standard of care when our other standard of care approach (use of Werewolf FLOW 50 electrocautery device) is not used.
Study: NCT06581380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK-1201I
Description: JK-1201I will be administered as an IV infusion at dose of 180mg/m2 on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan will be administered per drug label.
Study: NCT06582017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QXL138AM Injection every 2 weeks by IV Infusion
Description: masked immuno-cytokine comprised of an anti-CD138 IgG1 antibody fused to human interferon alpha 2a
Study: NCT05113030

Intervention type: OTHER
Intervention: PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADOLESCENT AGE GROUP WILL BE ASSESSED
Description: Test group(1st) enrollment criteria in PCOS group will be females of adolescent age newly diagnosed with PCOS, with \>16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
Study: NCT05113030

Intervention type: OTHER
Intervention: PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADULT AGE GROUP WILL BE ASSESSED
Description: Test group(2 nd) enrollment criteria in PCOS group will be females of adult age newly diagnosed with PCOS, with \>16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
Study: NCT05843929

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LSCI
Description: 1. A technician delivers a service at the home of the patient, who may be subject to different risk of ulcer, with the aim to analyse his/her foot through an integrated set of measurement technologies, based on:a-the piezoelectric insole that replaces missing pain sensation;b- Laser speckle contrast imaging technique (LSCI) that measures the blood flow;c- the multi points temperature device.~2. Data collected by the technician are sent via internet~3. On the basis of the clinical evaluation and doctor's report on points of foot sensitivity, a 3D model of the foot is created and used by the chiropodist;~4. Using the 3D model of the foot, the chiropodist uses a 3D Editor to design the 3D Model of the insole to enable the production of a tailored insole for the patient shoes~5. The final manufactured insole is then delivered to the patient;~6. A check survey is periodically carried out by the technician to scan the diabetic foot status progress
Study: NCT05519007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-Rinse Solution (NS)
Description: The surgical site will be irrigated with NS prior to closure,

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline irrigation
Description: The surgical site will be irrigated with Saline
Study: NCT04842383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemp Oil
Description: Hemp oil extract rich in varins (THCV and CBDV) as well as cannabidiol (CBD) in combination with 3% peppermint oil extract

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemp Oil
Description: Hemp oil extract rich in varins (THCV and CBDV) as well as cannabidiol (CBD) in combination with 3% peppermint oil extract
Study: NCT04784559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.